HALO logo
halo search icon
GMAB
Genmab A/S

GMAB · Genmab A/S

1708.00

DKK
53.00 (3.20%)
23/06/2026 12:00:00 AM
+1
Price change (7D)

Unlock stock Insights

Create a free account to unlock price targets, recommendations, and commentary.

Overview

Market Cap

kr106.53B

PE

19.80

EV/EBITDA

17.2

DIV Yield

0%

Payout Ratio

0%

MQV Rating

5Very Weak

As at 23/06/2026 12:00:00 AM

Price Chart

Description

Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline includes daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma, teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease, and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998, and is headquartered in Copenhagen, Denmark.

  • All-Companies
  • All-Consensus
  • Consensus Cheap
  • HALO 100
  • HALO 50
  • HALO All
  • HALO Consensus Value
  • HALO Small

Key Fundamentals

EPS 3 yr Growth

31.50%

EBITDA Margin

35.50%

Operating Cashflow

$1,186m

Free Cash Flow Return

14.60%

ROIC

11.90%

Interest Coverage

21.70

Quick Ratio

2.00

Performance

52 weeks range

Low 1275 - 2257

Trade Value (12mth)

US$9,236,902.00

1 week

9.8%

1 month

-0.87%

YTD

-14.87%

1 year

24.07%

All time high

3327.00

Additional Data

Shares Outstanding (Fully Diluted)

64m

HALO Sector

Healthcare

Next Company Report Date

24-Feb-27

Next Ex Dividend Date

N/A

Next Dividend Pay Date

N/A

Reporting Currency

USD

Short Sell (% of issue)

0.00

Consensus

Lock Icon

Unlock full consensus

Consensus score

Lock Icon/10

Recommendation

Buy

Target price

Lock Icon

Deviation

Lock Icon

Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

Mqv

Very Weak

Garp

Very Weak

Mqv Small

Very Weak

Momentum

Price

Neutral

Earnings

Very Weak

Growth

Earnings

Very Weak

Dividends

Very Weak

Quality

Capital Efficiency

Neutral

Balance Sheet

Very Weak

Valuation

Lock Icon

Unlock full dataset

Value

Lock Icon

Consensus

Lock Icon

Yield

Lock Icon

News & Announcements

No announcements available.

See beyond the curve.

One solution for research, investing and portfolio management.
Start FREE Trial
Want to learn more?Frequently asked questions.
1
What is the current share price of Genmab A/S (GMAB:CSE)?
Halo FAQ
The current share price of Genmab A/S (GMAB:CSE) is DKKkr1708.00.
2
What is the 52-week high share price for Genmab A/S (GMAB:CSE)?
Halo FAQ
The 52-week high share price for Genmab A/S (GMAB:CSE) is DKKkr2257.00.
3
What is the 52-week low share price for Genmab A/S (GMAB:CSE)?
Halo FAQ
The 52-week low share price for Genmab A/S (GMAB:CSE) is DKKkr1275.00.
4
What is the dividend yield for Genmab A/S (GMAB:CSE)?
Halo FAQ
Genmab A/S (GMAB:CSE) does not pay a dividend.
5
What was Genmab A/S (GMAB:CSE) last dividend payment?
Halo FAQ
Genmab A/S (GMAB:CSE) does not pay a dividend.
6
What is the franking level for Genmab A/S (GMAB:CSE)?
Halo FAQ
Genmab A/S (GMAB:CSE) has a franking level of 0.00%.
7
In which sector is Genmab A/S (GMAB:CSE) classified?
Halo FAQ
Genmab A/S (GMAB:CSE) is classified in the Healthcare.
8
What is the price-to-earnings (P/E) ratio for Genmab A/S (GMAB:CSE)?
Halo FAQ
The current P/E ratio for Genmab A/S (GMAB:CSE) is 19.80.